Subtype
Extrapulmonary Neuroendocrine Carcinoma
CI-CAN-00002658Explore in graph →
104 active trials6 approved drugs22 evidence items
- NCIt
- C191977
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002658Explore in graph →
Clinical trials
315 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (50)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07720193 | A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC | not yet recruiting | Phase 3 | 280 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05058651 | Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung | suspended | Phase 2 / Phase 3 | 189 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 |
| clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03271372 | Adjuvant Avelumab in Merkel Cell Cancer(ADAM) | active not recruiting | Phase 3 | 101 | University of WashingtonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531) | active not recruiting | Phase 3 | 291 | Loxo Oncology, Inc.INDUSTRY | 20 | Mar 19, 2026 | clinicaltrials |
| NCT07383246 | CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC(CAST-MTC) | recruiting | Phase 3 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03783078 | Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) | completed | Phase 3 | 55 | Merck Sharp & Dohme LLCINDUSTRY | 8 | May 28, 2025 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT01373736 | 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | unknown | Phase 3 | — | Vancouver Coastal HealthOTHER_GOV | 1 | Jun 15, 2011 | clinicaltrials |
| NCT00428597 | A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors | terminated | Phase 3 | 171 | PfizerINDUSTRY | 11 | Oct 11, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials